Regulatory Story
Go to market news section View chart   Print
Alliance Pharma PLC  -  APH   

CULS Conversion

Released 07:00 12-Feb-2013

RNS Number : 6468X
Alliance Pharma PLC
12 February 2013

For immediate release

12 February 2013



("Alliance" or the "Company")


CULS Conversion and Additional Listing


Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has received conversion requests in respect of £100,000 nominal value of the Company's 8% Convertible Unsecured Loan Stock.  Accordingly, the Company has allotted 476,190 ordinary shares of 1 pence each in the Company ("Ordinary Shares"), subject to admission of the Ordinary Shares to trading on AIM.


Application has been made by Alliance for the 476,190 Ordinary Shares to be admitted to trading on AIM, and it is expected that these new Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares, will be admitted to trading on 15 February 2013.


Following conversion and allotment, Alliance will have 244,487,512 Ordinary Shares and £3,911,255 of 8% Convertible Unsecured Loan Stock in issue.



For further information:


Alliance Pharma plc

+ 44 (0) 1249 466966

John Dawson, Chief Executive

Richard Wright, Finance Director


+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Oliver Cardigan

Corporate Broking: David Poutney


Notes to editors:


About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.



Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


CULS Conversion - RNS